🇺🇸 FDA
Pipeline program

ETIDRONATE DISODIUM ORAL CAPSULES 400 MG PLACEBO, ETIDRONATE DISODIUM ORAL CAPSULES 400 MG

22U-0320

Phase 2 small_molecule active

Quick answer

ETIDRONATE DISODIUM ORAL CAPSULES 400 MG PLACEBO, ETIDRONATE DISODIUM ORAL CAPSULES 400 MG for Fahr's disease, Fahr's syndrome is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
Fahr's disease, Fahr's syndrome
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials